WO2001025273A3 - Compositions and methods for wt1 specific immunotherapy - Google Patents

Compositions and methods for wt1 specific immunotherapy Download PDF

Info

Publication number
WO2001025273A3
WO2001025273A3 PCT/US2000/027465 US0027465W WO0125273A3 WO 2001025273 A3 WO2001025273 A3 WO 2001025273A3 US 0027465 W US0027465 W US 0027465W WO 0125273 A3 WO0125273 A3 WO 0125273A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
polypeptide
specific immunotherapy
presenting
Prior art date
Application number
PCT/US2000/027465
Other languages
French (fr)
Other versions
WO2001025273A2 (en
WO2001025273A9 (en
Inventor
Yasir A W Skeiky
Jiangchun Xu
Martin A Cheever
Steven G Reed
Original Assignee
Corixa Corp
Yasir A W Skeiky
Jiangchun Xu
Martin A Cheever
Steven G Reed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp, Yasir A W Skeiky, Jiangchun Xu, Martin A Cheever, Steven G Reed filed Critical Corixa Corp
Priority to AU78599/00A priority Critical patent/AU7859900A/en
Publication of WO2001025273A2 publication Critical patent/WO2001025273A2/en
Publication of WO2001025273A3 publication Critical patent/WO2001025273A3/en
Publication of WO2001025273A9 publication Critical patent/WO2001025273A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.
PCT/US2000/027465 1999-10-04 2000-10-04 Compositions and methods for wt1 specific immunotherapy WO2001025273A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU78599/00A AU7859900A (en) 1999-10-04 2000-10-04 Compositions and methods for wt1 specific immunotherapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15745999P 1999-10-04 1999-10-04
US60/157,459 1999-10-04

Publications (3)

Publication Number Publication Date
WO2001025273A2 WO2001025273A2 (en) 2001-04-12
WO2001025273A3 true WO2001025273A3 (en) 2002-07-11
WO2001025273A9 WO2001025273A9 (en) 2003-01-30

Family

ID=22563814

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/027465 WO2001025273A2 (en) 1999-10-04 2000-10-04 Compositions and methods for wt1 specific immunotherapy

Country Status (2)

Country Link
AU (1) AU7859900A (en)
WO (1) WO2001025273A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CA2286304C (en) 1997-04-10 2007-08-07 Diagnocure Inc. Pca3, pca3 genes, and methods of use
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
EP1222266B1 (en) 1999-09-29 2006-03-29 Diagnocure Inc. Pca3 messenger rna in benign and malignant prostate tissues
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
DE60238958D1 (en) * 2001-06-29 2011-02-24 Chugai Pharmaceutical Co Ltd A cancer vaccine with a cancer antigen based on the product of the tumor suppressing gene WT1 and a cationic liposome
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
CA2487907A1 (en) * 2002-06-11 2003-12-18 Glaxosmithkline Biologicals S.A. Immunogenic compositions comprising a xenogenic prostate protein p501s
CA2497554A1 (en) * 2002-09-20 2004-04-01 Dendreon Corporation Immunotherapeutic compositions and methods for the treatment of moderately to well-differentiated cancers
CA2513780C (en) 2003-02-07 2014-12-30 Diagnocure Inc. Method to detect prostate cancer from a urine sample
ATE462003T1 (en) * 2004-03-31 2010-04-15 Int Inst Cancer Immunology Inc CANCER ANTIGEN PEPTIDES DERIVED FROM WT1
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
EP1951281B1 (en) 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
PL1988163T3 (en) 2006-02-22 2012-11-30 Int Inst Cancer Immunology Inc Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
AU2012227350C1 (en) * 2006-12-28 2015-11-12 International Institute Of Cancer Immunology, Inc. HLA-A*1101-Restricted WT1 peptide and pharmaceutical composition comprising the same
DK2341142T3 (en) 2006-12-28 2014-12-08 Int Inst Cancer Immunology Inc HLA-A * 1101-restricted WT1 peptide or pharmaceutical composition comprising this
WO2009066462A1 (en) * 2007-11-20 2009-05-28 Nec Corporation Method for induction of cytotoxic t-cell, cytotoxic t-cell inducer, and pharmaceutical composition and vaccine each comprising the inducer
AR076349A1 (en) * 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc CANCER ANTIGEN AUXILIARY PEPTIDE
CN104684577B (en) 2012-01-13 2018-05-08 纪念斯隆凯特林癌症中心 Immunogenicity WT-1 peptides and its application method
PT2945647T (en) 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CA2840988A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for mucosal administration
MA43283B1 (en) 2015-11-20 2022-08-31 Memorial Sloan Kettering Cancer Center Composition for the treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029995A1 (en) * 1994-04-28 1995-11-09 The Wistar Institute Of Anatomy And Biology Wt1 monoclonal antibodies and methods of use therefor
WO2000018795A2 (en) * 1998-09-30 2000-04-06 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
EP1103564A1 (en) * 1998-07-31 2001-05-30 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029995A1 (en) * 1994-04-28 1995-11-09 The Wistar Institute Of Anatomy And Biology Wt1 monoclonal antibodies and methods of use therefor
EP1103564A1 (en) * 1998-07-31 2001-05-30 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
WO2000018795A2 (en) * 1998-09-30 2000-04-06 Corixa Corporation Compositions and methods for wt1 specific immunotherapy

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DEAVIN A J ET AL: "STATISTICAL COMPARISON OF ESTABLISHED T-CELL EPITOPE PREDICTORS AGAINST A LARGE DATABASE OF HUMAN AND MURINE ANTIGENS", MOLECULAR IMMUNOLOGY,US,ELMSFORD, NY, vol. 33, no. 2, 1996, pages 145 - 155, XP000884372, ISSN: 0161-5890 *
GAIGER A ET AL: "A NEW LEUKEMIA AND CANCER ANTIGEN", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, PHILADELPHIA, PA: AACR, US, vol. 40, March 1999 (1999-03-01), pages 424 - #2802, XP000876782 *
GAIGER A ET AL: "IMMUNITY TO WT1 IN ANIMAL MODELS AND LEUKEMIA PATIENTS", BLOOD,US,W.B. SAUNDERS, PHILADELPHIA, VA, vol. 94, no. 10, 15 November 1999 (1999-11-15), pages 78, XP000876777, ISSN: 0006-4971 *
OKA Y ET AL: "CANCER IMMUNOTHERAPY TARGETING WILMS' TUMOR GENE WT1 PRODUCT", JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO, US, vol. 164, no. 4, 15 February 2000 (2000-02-15), pages 1873 - 1880, XP001004429 *
OKA Y ET AL: "HUMAN CYTOTOXIC T-LYMPHOCYTE RESPONSES SPECIFIC FOR PEPTIDES OF THEWILD-TYPE WILMS' TUMOR GENE (WT1) PRODUCT", IMMUNOGENETICS, SPRINGER VERLAG, BERLIN, DE, vol. 51, no. 2, February 2000 (2000-02-01), pages 99 - 107, XP001004508, ISSN: 0093-7711 *
PROCEEDINGS OF THE 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. PHILADELPHIA, PA, APRIL 10 - 14, 1999, *
RAMMENSEE H-G ET AL: "MHC LIGANDS AND PEPTIDE MOTIFS: FIRST LISTING", IMMUNOGENETICS, SPRINGER VERLAG, BERLIN, DE, vol. 41, 1995, pages 178 - 228, XP002922231, ISSN: 0093-7711 *
RAUSCHER FJ 3RD, MORRIS JF, FREDERICKS WJ, LOPEZ-GUISA J, BALAKRISHNAN C, JOST M, HERLYN M, RODECK U: "Characterization of monoclonal antibodies directed to the amino-terminus of the WT1, Wilms' tumor suppressor protein.", HYBRIDOMA, vol. 17, no. 2, April 1998 (1998-04-01), pages 191 - 198, XP001006113 *
ROTHBARD, J. B. & TAYLOR, W.R.: "A sequence pattern common to T cell epitopes", EMBO JOURNAL, vol. 7, no. 1, 1988, EYNSHAM, OXFORD GB, XP000877127 *

Also Published As

Publication number Publication date
AU7859900A (en) 2001-05-10
WO2001025273A2 (en) 2001-04-12
WO2001025273A9 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
WO2000018795A3 (en) Compositions and methods for wt1 specific immunotherapy
WO2003037060A3 (en) Compositions and methods for wt1 specific immunotherapy
AU9660801A (en) Compositions and methods for wt1 specific immunotherapy
WO2001025273A3 (en) Compositions and methods for wt1 specific immunotherapy
WO2004100870A3 (en) Compositions and methods for wt1 specific immunotherapy
WO2002014503A3 (en) Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies
WO2004058171A3 (en) Antibodies against gpr64 and uses thereof
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
WO2000020864A8 (en) Immunotherapy of b cell involvement in progression of solid, nonlymphoid tumors
WO2002060317A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
SI1187632T1 (en) TREATMENT WITH ANTI-ErbB2 ANTIBODIES
MXPA03000527A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer.
CA2093667A1 (en) Mouse monoclonal antibodies and uses thereof
WO2000066528A3 (en) Quinones for treatment of diseases
WO2002078516A3 (en) Compositions and methods for the therapy and diagnosis of cancer
AU3052799A (en) Pharmaceutical compositions comprising erythropoietin for treatment of cancer
WO2005019435A3 (en) Anti-cancer vaccines
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
WO2002039885A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2003026494A3 (en) Galectins-1-and-4 in tumor development
WO2003024302A3 (en) Detection and treatment of cancers of breast
WO2003024304A3 (en) Detection and treatment of cancers of the liver
WO2000004153A3 (en) Repression of cell transformation with human pea3
WO2003081250A8 (en) Novel compositions and methods in cancer associated with altered expression of prlr

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
COP Corrected version of pamphlet

Free format text: PAGES 1/17-17/17, DRAWINGS, REPLACED BY NEW PAGES 1/17-17/17; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WPC Withdrawal of priority claims after completion of the technical preparations for international publication

Ref country code: WO

NENP Non-entry into the national phase

Ref country code: JP